Pharmaceutical industry

Robbins LLP Announces It Has Filed a Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc.

Retrieved on: 
Thursday, August 18, 2022 - 12:51am
Class Action Lawsuit, Professional Services, Legal, Steps, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Electric Bond and Share Company v. Securities and Exchange Commission, Osteoarthritis, NYSE, OAK, Securities Exchange Act of 1934, District, Pain, Advertising, Efficacy, Douglas v. U.S. District Court ex rel Talk America, Court, Lists of schools in England, Company, Next Step Realty, District court, Knee, Food, Person, Complaint, Pharmaceutical industry

The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Ampio during the Class Period.

Key Points: 
  • The complaint seeks relief on behalf of the named plaintiff and all other similarly situated holders of Ampio during the Class Period.
  • The named plaintiff is represented by Robbins LLP.
  • Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion's efficacy.
  • About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

MNSO ALERT: Hagens Berman, National Trial Attorneys, Encourages MINISO Group Holdings (MNSO) Investors with Losses to Contact the Firm’s Attorneys, IPO-Related Securities Class Action Filed

Retrieved on: 
Wednesday, August 17, 2022 - 11:20pm
Steve Berman (lawyer), NYSE, GLOBE, SEC, American depositary receipt, Public expenditure, MNSO, Person, SAN, Program, Fraud, News, Security (finance), Pharmaceutical industry, IPO

SAN FRANCISCO, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges MINISO Group Holdings Limited (NYSE: MNSO) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges MINISO Group Holdings Limited (NYSE: MNSO) investors who suffered significant losses to submit your losses now .
  • A securities class action related to MINISOs Oct. 15, 2020, initial public offering of approximately 30.4 million American Depositary Shares at $20/share has been filed.
  • On July 26, 2022, analyst Blue Orca Capital published a scathing report concluding in part that MINISO owns and operates about 40% of MINISO stores.
  • As of the date of the filing of the action, MINISOs ADSs trade almost 70% below the IPO price.

HAGENS BERMAN, National Trial Attorneys, Encourages Co-Diagnostics (CODX) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Wednesday, August 17, 2022 - 11:05pm
SEC, News, Person, Complaint, Program, Steve Berman (lawyer), Fraud, Lists of schools in England, NASDAQ, Test, COVID-19, Tobacco, Pharmaceutical industry

As a result, Defendants positive statements about the demand for the Logix Smart COVID-19 Test lacked a reasonable basis.

Key Points: 
  • As a result, Defendants positive statements about the demand for the Logix Smart COVID-19 Test lacked a reasonable basis.
  • Investors began to learn the truth, according to the complaint, on Aug. 11, 2022, when Co-Diagnostics announced disastrous financial results for Q2 2022.
  • Were focused on investors losses and proving Defendants misled investors about the real demand for Co-Diagnostics test, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Co-Diagnostics and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC

Retrieved on: 
Wednesday, August 17, 2022 - 11:10pm
Class Action Lawsuit, Professional Services, Legal, Titan, TO, Clinical trial, BPMC, Facebook, Part Two, Advertising, Patient, Twitter, I-Space (Chinese company), WHY, NASDAQ, SM, News, LinkedIn, Blueprint, Security (finance), Pharmaceutical industry

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

Key Points: 
  • WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.

Gabelli Merger Plus+ Trust plc Update on Share Purchase Offer

Retrieved on: 
Wednesday, August 17, 2022 - 11:49pm
Banking, Professional Services, Finance, Investment, Board, Loyalty, Financial services, Person, Registered, Circular, EU, RNS, News, Regulation, Financial Services and Markets Act 2000, Securities Act of 1933, Sale, GMP, Nature, Business Process Framework (eTOM), Portfolio manager, United Kingdom, LTD, Offering circular, LLC, European Economic Area, Compliance, Income, Finance, Trustee, Mario Gabelli, Time, Mass meeting, Common stock, Review, Company, Prognosis, Section 21, FSMA, General officer, Forward, Admission, Completeness, EEA, Pharmaceutical industry, Security (finance), Management, Risk management, Property management, Real estate, Bank, Directive 2014/65/EU

Gabelli Funds, LLC, the investment adviser of Gabelli Merger Plus+ Trust plc (the Company), is providing shareholders, as general information, certain details of the Companys tender offer to purchase certain Ordinary Shares (Offer) in advance of publication of the Offering Circular (Circular), and follows the Companys March 23, 2022 announcement.

Key Points: 
  • Gabelli Funds, LLC, the investment adviser of Gabelli Merger Plus+ Trust plc (the Company), is providing shareholders, as general information, certain details of the Companys tender offer to purchase certain Ordinary Shares (Offer) in advance of publication of the Offering Circular (Circular), and follows the Companys March 23, 2022 announcement.
  • Shareholders should contact Gabelli Funds at GMPteam@gabelli.com to ensure their necessary evidentiary supporting materials are satisfactory and for any general assistance.
  • The Gabelli Merger Plus+ Trust (GMP) was launched in July 2017 to access Gabellis long term efforts in merger investing.
  • The investment backdrop for the Gabelli Merger Plus+ Trust is robust and positively oriented for returns.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sema4 Holdings Corp. (SMFR, SMFRW) on Behalf of Investors

Retrieved on: 
Wednesday, August 17, 2022 - 11:30pm
Class Action Lawsuit, Professional Services, Legal, FDA, Press, Real estate investment trust, Industry, Associated Press, SEC, DOJ, Investment, GPM, SCAS, Research, Workforce, Information technology, SMFR, Company, Person, Acquisition, Program, NASDAQ, Bloomberg Businessweek, Publication, News, Financial Times, Insurance, The Wall Street Journal, Pharmaceutical industry, Reuters, Forbes

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sema4 Holdings Corp. (Sema4 or the Company) (NASDAQ: SMFR , SMFRW ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sema4 Holdings Corp. (Sema4 or the Company) (NASDAQ: SMFR , SMFRW ) investors concerning the Companys possible violations of the federal securities laws.
  • Less than a year later, on June 14, 2022, Sema4 announced that its Chief Financial Officer had departed.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

How Might Biomolecular Condensates Revolutionize Drug Discovery? A Perspective from Dewpoint Therapeutics

Retrieved on: 
Wednesday, August 17, 2022 - 11:59pm
Condensate, Multimedia, Drug discovery, Cancer, Cardiomyopathy, Coronavirus Scientific Advisory Board (Turkey), Nature Reviews Drug Discovery, Hope, Epistasis, Patient, Therapy, Degenerative disease, Dew point, Biology, Neurodegeneration, Logic, Disease, Pharmaceutical industry, Medical device

BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.

Key Points: 
  • BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.
  • In "Modulating biomolecular condensates: a novel approach to drug discovery," a Dewpoint Therapeutics perspective, the authors discuss the largely untapped opportunities for targeting biomolecular condensates to develop therapeutic agents for various diseases.
  • Condensate-targeted drug discovery was pioneered by Dewpoint Therapeutics as the firstbiotech company to enter the field, founded in 2018.
  • Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.

Plus Therapeutics Awarded $17.6 Million from State of Texas

Retrieved on: 
Wednesday, August 17, 2022 - 10:46pm
Woman, U.S. Securities and Exchange Commission, Texas Legislature, Cancer prevention, Metastasis, LM, GLOBE, Food, Neoplasm, Diagnosis, Research institute, Cancer, Cancer Prevention and Research Institute of Texas, Research, Perception, Patient, Therapy, Company, Lone Star, Cohort, Program, Breast cancer, Radiation, Central nervous system, Safety, Nasdaq, Fast Track, Financial toxicity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Data monitoring committee, PSTV, Organization, Pharmaceutical industry

AUSTIN, Texas, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the continued development of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM).

Key Points: 
  • The Plus team is honored to receive this significant and esteemed award from CPRIT, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • In the second quarter of 2022, the Company completed enrollment of Cohort 1 in the ReSPECT-LM Phase 1/2a dose escalation trial ( NCT05034497 ).
  • To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.
  • Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 17, 2022 - 10:00pm
U.S. Securities and Exchange Commission, Risk, Pharmacy, Industry, Forward-looking statement, Legislation, MB, Growth, TSX Venture Exchange, Research, Government, Perception, Marketing, Patient, Company, Health status of Asian Americans, OTC, United States Food Administration, Conference call, Tablet, Internet, Conference, Pharmaceutical industry, Online shopping

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unilever PLC - UL

Retrieved on: 
Wednesday, August 17, 2022 - 10:02pm
Movement, Â, CEO, Pomerantz, NYSE, GLOBE, BDS, Environment, Company, LLP, Letter, Contract, Twitter, Acquisition, CNBC, Scrutineer, Ice cream, Legislation, Risk management, Pharmaceutical industry, Unilever

NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unilever PLC (Unilever or the Company) (NYSE: UL).Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.

Key Points: 
  • NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unilever PLC (Unilever or the Company) (NYSE: UL).Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.
  • The investigation concerns whether Unilever and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • More than 20 years after the acquisition, Ben & Jerrys remains a wholly owned subsidiary of Unilever with an independent board addressing the companys Social Mission.
  • The letter also stated that Florida would then be prohibited from investing in Ben & Jerrys or its parent company, Unilever.